Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that Carmine Stengone, CEO of Pipeline, will present on June 9, 2023 at 12:15pm ET at the 2023 Jefferies Global Healthcare Conference, being held June 7-9, 2023 in New York, NY. Company management will also participate in one-on-one meetings with investors during the conference.

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. In April 2023, Pipeline announced that it entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen) for its lead program, PIPE-307, a highly selective M1 antagonist, in nervous system disorders. The Company’s second program, PIPE-791, an LPA1 receptor antagonist, has completed IND-enabling studies and is advancing toward clinical development for remyelination and neuroinflammation.

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005134/en/